The evolving landscape of amyloid-targeting therapies in Alzheimer’s disease: progress and challenges

Monoclonal antibodies including aducanumab, lecanemab, and donanemab achieve significant amyloid clearance and modest slowing of cognitive decline in Phase 3 trials, validating amyloid reduction as a disease-modifying pathway.